Management
Dr. Eran Eden
Co-founder & CEO
Dr. Eden has been the CEO of MeMed since its inception in 2009, leading it from an idea to a rapidly growing company. He has 14 years of combined business and academic experience leading the development of cutting-edge multidisciplinary technologies that synergize molecular biology and informatics. Dr. Eden co-founded several highly funded international consortia (e.g., Tailored-Treatment, Respiratory-ImmunoDx, AutoPilotDx), the mission of which is to develop, clinically validate and commercialize novel technologies for diagnosing patients with infectious diseases and inflammatory disorders. He holds a B.Sc. in Computer Engineering, B.A. in Biology, and M.Sc. in Computer Science (all Cum Laude) from the Technion, Israel Institute of Technology, and a Ph.D. in Systems Biology from the Weizmann Institute of Science. Dr. Eden is co-author of over 20 patents and 20 peer-reviewed publications, and is the recipient of multiple awards including the prestigious GE and Science Prize for Promising Life Scientists
Dr. Kfir Oved
Co-Founder, CTO & Chairman of the Board
Dr. Oved co-founded MeMed in 2009 and serves as its CTO and Chairman of the Board. As a bioentrepreneur, he has 15 years of combined industry and academic experience, leading interdisciplinary projects that apply molecular immunology and systems immunology-based technologies to clinical applications. He holds a B.A. in Biology (Summa Cum Laude), B.Sc. in medicine (Magna Cum Laude), Ph.D. in molecular immunology, and 6 years training at the Technion, Israel Institute of Technology Medical school. He served as a scientific advisor at Applied Immune Technologies (acquired by Adicet in 2016) and is the co-author of 83 granted patents and pending applications relating to 20 different patent families. Dr. Oved led development and clinical validation of the MeMed BV™ technology, and also the build of the MeMed Key™ Point of care platform, from conceptualization to development completion. He is the author of 14 peer-reviewed publications, and the recipient of multiple research excellence awards, including the prestigious Wolf Award for research students.
Mr. Idan Danenberg
Chief Operating Officer
Mr. Danenberg has over 15 years of leadership experience in international operations and supply chain, service and lean manufacturing in the pharmaceutical and medical device industries. Before joining MeMed’s team, Mr. Danenberg led the global operations, supply chain and service as COO for Degania Medical, a world leader for disposable catheters, cardiovascular catheters, and custom procedure trays, with 6 manufacturing plants and 3 logistics sites globally. Prior to that, Mr. Danenberg held the position of VP Operations for Taro Pharmaceuticals (NYSE: TARO), a multinational manufacturer of OTC and Rx oral solid dosage, semi-solid and liquid formulations. He led the operations of the Israeli and Canadian sites. Mr. Danenberg holds a B.Sc in Biotechnology and Food Engineering from the Technion – Israel Institute of Technology, and an MBA from Haifa University.
Mr. Ofer Halbreich
VP Commercial & Corporate Development
Mr. Halbreich LLB, MBA, has 20 years of professional experience in diverse commercial negotiations and engagements, business development, strategic planning, M&As and global operations. Prior to joining MeMed’s team, Mr. Halbreich led the global operations activity of MediaMind Technologies Inc., and following its purchase by Digital Generation Inc. (Nasdaq: DGIT), led the global operations integration process of the companies. Prior to that, Mr. Halbreich was the COO of Neuronix Medical, an innovative medical device company in the field of Alzheimer’s disease treatment. Before that, Mr. Halbreich acted as VP of Business Development & Legal Counsel for Office Depot (Israel). Mr. Halbreich also served as a commercial lawyer for some of Israel’s most prominent law firms, handling large-scale commercial activities including M&A, joint ventures, licensing and investment agreements. Mr. Halbreich holds an LLB from the Hebrew University of Jerusalem and an MBA (Finance) from the Interdisciplinary Center in Herzliya.
Dr. Tanya Gottlieb
VP Scientific Affairs
Dr. Gottlieb has over 25 years of experience in academia and industry, specializing in building international collaborations and securing non-dilutive financing, including multi-million government contracts. Before joining MeMed, Dr. Gottlieb was Director of Business Development at BiondVax Pharmaceuticals Ltd (NASDAQ: BVXV), an innovative developer of a universal influenza vaccine. Dr. Gottlieb holds a BA in Natural Sciences and PhD in molecular biology from Cambridge University and an MBA from the Technion – Institute of Technology, Israel. Between completing her doctorate and entering biotech, Dr. Gottlieb was a postdoctoral fellow at the Weizmann Institute of Science, Israel and the Fred Hutchinson Cancer Research Center in Seattle, WA, USA. In 2004 Dr. Gottlieb founded Gottlieb Scientific Communications, which she ran for 10 years. Dr. Gottlieb is co-author of over 20 peer reviewed publications and the recipient of multiple awards, including the Royal Society (UK)-Israel Academy Postdoctoral Fellowship.
Ms. Noga Salomon
VP Engineering
Ms. Salomon has more than a decade experience in the medical device industry. Prior to joining MeMed’s team, Ms. Salomon was a part of the R&D systems group at Biosense Webster Inc, a J&J company that is a world leader in cardiac arrhythmia treatment. As a systems engineer, Ms. Salomon co-led the development of the ConfiDENSE™️ module, which later went on to win the J&J Hofmann award for innovation in 2016. Ms. Salomon has extensive experience in cardiac signal processing, systems engineering, cross-functional team management and medical device development processes. Ms. Salomon holds a B.Sc. in Electrical Engineering from the Technion-Israel Institute of Technology.